The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials

Future Oncol. 2016 Sep;12(18):2061-3. doi: 10.2217/fon-2016-0040. Epub 2016 May 11.
No abstract available

Keywords: CheckMate 025; anti-PD-1; immune-checkpoint inhibitors; immunotherapy; kidney cancer; nivolumab; renal cell carcinoma; therapy.

Publication types

  • Editorial
  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / mortality
  • Carcinoma, Renal Cell / pathology
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / mortality
  • Kidney Neoplasms / pathology
  • Molecular Targeted Therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Programmed Cell Death 1 Receptor